Last reviewed · How we verify

Goofice (ELOBIXIBAT)

EA Pharma · discontinued Small molecule

Goofice works by inhibiting the ileal sodium/bile acid cotransporter to stimulate bowel movements.

Goofice (Elobixibat) is a small molecule modality developed by EA Pharma, targeting the ileal sodium/bile acid cotransporter. It is used to treat chronic constipation. The commercial status of Goofice is patented, with EA Pharma being the current owner. Key safety considerations include the need for further research on its long-term effects. Goofice works by inhibiting the ileal sodium/bile acid cotransporter, which reduces bile acid reabsorption and increases bile acid excretion, thereby stimulating intestinal motility and promoting bowel movements.

At a glance

Generic nameELOBIXIBAT
SponsorEA Pharma
TargetIleal sodium/bile acid cotransporter
ModalitySmall molecule
Therapeutic areaGastroenterology
Phasediscontinued

Mechanism of action

Imagine your intestines as a highway where bile acids are like cars. Normally, these cars get picked up and reabsorbed, but Goofice blocks this process, causing the cars to pile up and stimulate the intestines to move them along, resulting in a bowel movement.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: